ROIV Stock: Price, Earnings History and SEC Filings
Roivant Sciences Ltd. (ROIV) last traded at $36.91, down 1.63% on the latest session and up 0.9% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.45 against an analyst estimate of $-0.45, a beat of 0.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ROIV earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.45 | $-0.45 | +0.00% |
| Mar 2026 | May 20, 2026 | $-0.46 | $-0.38 | -21.05% |
| Dec 2025 | Feb 6, 2026 | $-0.36 | $-0.39 | +7.69% |
| Sep 2025 | Nov 10, 2025 | $-0.40 | $-0.34 | -17.65% |
ROIV beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
How ROIV reacts to earnings
Across its last 8 earnings releases, ROIV moved 6.6% on average the next session, in either direction. It rose after 6 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-08-06 | Before open | +1.50% |
| 2026-05-20 | Before open | +14.89% |
| 2026-04-02 | Before open | +1.76% |
| 2026-02-06 | Before open | +22.14% |
| 2025-11-10 | Before open | +2.67% |
| 2025-08-11 | Before open | -2.79% |
| 2025-05-29 | Before open | +6.40% |
| 2025-02-10 | Before open | -0.92% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
ROIV financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2026 | $8M | -$300M | -$759M | -3629.2% | $-0.54 |
| 2025 | $29M | -$172M | -$844M | -592.0% | $-0.24 |
| 2024 | $33M | $4.3B | -$767M | 13294.2% | $5.23 |
| 2023 | $32M | -$1.0B | -$856M | -3200.2% | $-1.42 |
| 2022 | $55M | -$845M | -$695M | -1528.9% | $-1.26 |
| 2021 | $24M | -$809M | -$558M | -3400.9% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for ROIV
- 8-K · Oct 21, 2026Regulation FD disclosure, Financial statements and exhibits
- 8-K · Sep 18, 2026Shareholder vote, Financial statements and exhibits
- 8-K · Sep 8, 2026Regulation FD disclosure, Financial statements and exhibits
- 8-K · Aug 28, 2026Other events, Financial statements and exhibits
- 8-K · Aug 27, 2026Regulation FD disclosure, Financial statements and exhibits
- 10-Q · Aug 6, 2026
- 8-K · Aug 6, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Jul 29, 2026
- 10-K · May 20, 2026
- 8-K · May 20, 2026Results of operations, Financial statements and exhibits
Insider filing activity
ROIV insiders filed 34 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ROIV news
- Roivant Social Ventures Announced Support of No Patient Left Behind with Six-Figure Organizational Legacy GiftOct 29, 2026 · finance.yahoo.com
- Phathom Pharmaceuticals, Inc. (PHAT) Lags Q3 Earnings and Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- Roivant Soars 8% as Brepocitinib Delivers “Phenomenal Results” in Two Phase 3 Uveitis TrialsOct 23, 2026 · tikr.com
- Roivant Sciences’ Brepocitinib Delivers Positive Phase III Uveitis ResultsOct 21, 2026 · marketbeat.com
- Roivant Sciences stock surges on positive uveitis trial dataOct 21, 2026 · finance.yahoo.com
- Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026Oct 21, 2026 · finance.yahoo.com
- Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026Oct 21, 2026 · finance.yahoo.com
- Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)Oct 21, 2026 · finance.yahoo.com
About Roivant Sciences Ltd.
Roivant Sciences Ltd. (ROIV) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in Bermuda. Its fiscal year ends in March.